-
A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GOG 3107)
This study is being done to compare a new treatment, Rina-S, to standard chemotherapy in patients with a type of ovarian cancer that no longer ...
Phase
Interventional
-
IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients MAVERIC
The purpose of this research study is to evaluate if study treatment with CardiolRxTM will prevent pericarditis recurrences after the therapy when the IL-1 blocker ...Phase
Interventional
-
A Phase 3 Randomized Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)
This is a Phase 3 study testing whether the study medicine sacituzumab tirumotecan ( sac-TMT, antibody-drug conjugate (ADC) targeting TROP2), given alone or with pembrolizumab (immunotherapy ...
Phase
Interventional
-
A Phase 3 Double-blind Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2- negative Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive.
This is a Phase 3 study testing whether the study medicine zolbetuximab (monoclonal antibody), together with pembrolizumab (PD-L1 inhibitors ) and chemotherapy (CAPOX or mFOLFOX6), works ...
Phase
Interventional
-
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
The purpose of this research study is to assess the performance of a new prostate biopsy instrument called SUREcore Plus and participants tolerance of its ...Phase
Interventional
-
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
In this study, all patients will start with the same treatment using two drugs called topotecan and cyclophosphamide in the first cycle. After that, patents ...
Phase
Interventional
-
A Phase 3 Single-Arm Multiple-Dose Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The MIgGRATE Study is a clinical study for adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) of an investigational drug called TAK-881. In this study, TAK-881 ...Phase
Interventional
-
A Randomized Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-na ve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)
This is a Phase 2 study testing two different medicines to treat a blood cancer called GCB DLBCL(diffuse large B-cell lymhoma). Zilovertamab Vedotin (an ...
Phase
Interventional
-
A Randomised Open-Label Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1 BRCA2 or PALB2 Mutations and Hormone Receptor Positive HER2-Negative (IHC 0 1+ 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
This study is testing how well a new medicine, saruparib (AZD5305), works when combined with camizestrant compared to other common treatments for advanced breast cancer ...
Phase
Interventional
-
Global Phase 3 Randomized Open-Label Study to Evaluate Efficacy & Safety of Firmonertinib Comp.w/ Osimertinib or Afatinib as 1st line Treat. in Pts. w/ Locally Advanced or Metastatic NSCLC with EGFR PACC Uncommon Mutations (Alpacca)
This is a Phase 3 study testing the safety and effectiveness of the new medicine firmonertinib (an EGFR-tyrosine kinase inhibitor) and comparing it with standard ...
Phase
Interventional
